Onxeo to Present at the 18th Annual Rodman and Renshaw Global Investment Conference in New York
September 07, 2016 12:31 ET
|
Onxeo SA
PARIS & COPENHAGEN--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory
News:
Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO), an innovative company specialized
in the development of orphan...
Onxeo S.A.: Combination of AsiDNA and PARP Inhibitors Demonstrates Synergistic Effect, Bypasses Genetic Restriction
September 07, 2016 12:00 ET
|
Onxeo SA
Preclinical Research Published in Clinical Cancer Research
PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE (http://www.businesswire.com/))--
Regulatory News:
Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO)...
Onxeo Reports First-Half 2016 Business Update and Consolidated Financials
July 28, 2016 12:02 ET
|
Onxeo SA
Expansion of orphan oncology pipeline through acquisition of DNA Therapeutics
and lead compound AsiDNATM
Important development milestones on existing assets:
· Livatag® Phase III trial in HCC: 80%...
Onxeo Signs Exclusive License Agreement with Pint Pharma for the Commercialization of Beleodaq® in PTCL in South America
July 27, 2016 12:03 ET
|
Onxeo SA
•Agreement covering seven South American countries
•Onxeo to receive upfront payment, regulatory and commercial milestones, and
sales royalties for a total deal value greater than USD 20 million
PARIS...
Onxeo samarbejder med Royal College of Surgeons i Irland om forskningsprogram vedrørende derivater af Beleodaq®
July 07, 2016 14:05 ET
|
Onxeo SA
PARIS, Frankrig & KØBENHAVN, Danmark--(BUSINESS
WIRE (http://www.businesswire.com/))-- Fondsbørsmeddelelse:
Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), et innovativt selskab med
speciale i...
Onxeo collaborates with the Royal College of Surgeons in Ireland for research program on Beleodaq® derivatives
July 07, 2016 14:05 ET
|
Onxeo SA
PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE (http://www.businesswire.com/))--
Regulatory News:
Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ Copenhagen:
ONXEO), an innovative...
Onxeo Receives USPTO Notice of Allowance for Key AsiDNATM Patent, Extending IP Protection in the U.S. until 2031
July 04, 2016 02:00 ET
|
Onxeo SA
· Products, including AsiDNA (signal interfering DNA), protected until 2031
with potential extension to 2036
· Onxeo’s intellectual property for DNA repair signal interfering technology
and products...
Onxeo modtager “Notice of Allowance” fra de amerikanske patentmyndigheder for det primære AsiDNATM patent...
July 04, 2016 02:00 ET
|
Onxeo SA
· Produkter, herunder AsiDNA (signal-interfererende DNA), beskyttet indtil
2031 med mulig forlængelse til 2036
· Onxeos immaterielle rettigheder for DNA-reparations signal-interfererende
teknologi...
Onxeo offentliggør udviklingsplan for det innovative signal-interfererende DNA-produkt AsiDNA
June 27, 2016 12:48 ET
|
Onxeo SA
Forventelige milepæle på kort og langt sigt
PARIS & KØBENHAVN, Danmark--(BUSINESS WIRE (http://www.businesswire.com/))--
Regulatory News:
Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris,...
Onxeo advances development plan for first-in-class signal interfering DNA compound AsiDNA
June 27, 2016 12:48 ET
|
Onxeo SA
Near- and mid term expected milestones
PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE (http://www.businesswire.com/))--
Regulatory News:
Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris,...